Highest-materiality recent filing
Novocure Q1 net revenue $174M (+12% YoY); raises FY2026 guidance; Optune Pax launch
Net loss of $71.1M ($0.62 per share); Adjusted EBITDA of -$0.3M.
NovoCure discloses CEO Frank Leonard's pay: CHF 750K base, 90% target bonus, enhanced severance
Base salary of CHF 750,000 and target annual bonus of 90% of base (CHF 675,000).
NovoCure names Dr. Uri Weinberg CMO, adds CHF 5k/month stipend
Dr. Uri Weinberg, previously Chief Innovation Officer, also appointed Chief Medical Officer effective April 7, 2026.
Novocure PANOVA-4 trial meets primary endpoint; DCR 74.4% vs 48% historical control in mPDAC
PANOVA-4 met primary endpoint: DCR 74.4% (N=78) vs 48% historical control (N=431), 1-sided p<0.001.
Novocure reports Q4 2025 revenues up 8% to $174M; FDA approves Optune Pax for pancreatic cancer
FDA approved Optune Pax for locally advanced pancreatic cancer in Feb 2026; expands addressable market significantly.
CMS rescinds retroactive revocation of Novocure's Medicare billing privileges
CMS revoked billing privileges retroactive to Dec 17, 2025; cited administrative re-validation issue, not substantive failure.
FDA Approves Novocure's Optune Pax for Locally Advanced Pancreatic Cancer
FDA approval based on Phase 3 PANOVA-3 trial in 571 patients with locally advanced pancreatic cancer.
NovoCure receives CMS billing revocation; expects ~$13M/month revenue impact until reinstatement
CMS revoked NovoCure's billing privileges retroactive to Dec 17, 2025 due to an administrative re-validation process issue.
NovoCure reports record FY2025 revenue $655M (+8% YoY); appoints Frank Leonard as CEO
Preliminary FY2025 net revenue $655.4M (+8% YoY); Q4 revenue $174.4M (+8% YoY).
Novocure appoints President Frank Leonard as CEO; Ashley Cordova resigns
Ashley Cordova resigned as CEO and director effective Nov 30, 2025; no disagreement related to operations.
NovoCure Q3 revenue $167M (+8% YoY), net loss $37.3M; PMA for pancreatic cancer under review
Net revenues of $167.2M, up 8% YoY; US contributed $96.6M, Germany $20.3M, France $19.6M, Japan $9.4M.
Japan MHLW approves Novocure's Optune Lua for advanced NSCLC
Japan MHLW approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors in advanced/recurrent NSCLC after platinum-based chemo.
Novocure GmbH terminated the LUNAR-4 phase 2 trial of Tumor Treating Fields with pembrolizumab for metastatic non-small cell lung cancer.
NovoCure Q2 2025 revenue $158.8M (+6% YoY), net loss $40.1M; plans pancreatic cancer PMA in Q3
Net revenues $158.8M, up 6% YoY; net loss $40.1M ($0.36 loss per share); adjusted EBITDA -$9.9M.
NovoCure shareholders elect 11 directors, approve ESPP; President awarded 179,426 RSUs
Shareholders elected all 11 director nominees with >81M votes each; 92.98M shares represented (~83.4%).
Median overall survival 16.2 months with TTFields + GnP vs 14.2 months for GnP alone; HR 0.82, p=0.039.
In connection with his appointment of the title "President, Novocure" on June 4, 2025 (the "Award Date"), Francis Leonard, formerly the Company's Executive Vice President, President Novocure Oncology, was awarded 179,426 Restricted Share Units
Max materiality 0.85 · Median 0.72 · Most common event other_material